Tablets & Capsules


Issue link:

Contents of this Issue


Page 18 of 51

Tablets & Capsules July/August 2021 17 I excipients Dr. Christian Nowak Meggle Excipients & Technology Lactose-free coprocessed excipients for direct-compression tableting This article describes a new lactose-free coprocessed excip- ient designed for direct compression of sustained-release tablets and compares its functional performance to a physi- cal admixture of the same components. n 2009, Meggle introduced RetaLac, a combination of lactose monohydrate and hypromellose (HPMC) tai- lored specifically to sustained-release tablet formulation. The coprocessed excipient uses spray agglomeration to transform hypromellose into a granular powder dense enough to allow for sufficient powder flow and porous enough to deliver adequate compactibility for direct compression. It exhibits consistent water uptake and swelling behavior, allowing for drug release modeling (1), which has not been achieved using a physical admix- ture of the same ingredients.

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC0721